Eton Pharmaceutical ETON 深 沪
已收盘 08-01 16:00:00 美东时间
14.13
-0.030
-0.21%
华盛通- 最 高14.245
- 今 开14.10
- 成交量 24.95万股
- 最 低 13.7801
- 昨 收 14.16
- 总市值 3.79亿
- 52周最高 21.48
- 市盈率 静 --
- 换手率 0.93%
- 52周最低 3.6302
- 委 比 -62.34%
- 总股本 2681.75万
- 历史最高 21.48
- 量 比 0.83
- 振 幅 3.28%
- 历史最低 1.95
- 每 手 1
- 风险率 4.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Soligenix Completes Phase 2a Proof Of Concept Study Evaluating SGX945 In Behçet's Disease, Showing Biological Efficacy
PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases
07-31 19:37
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Eton Pharmaceuticals, Inc. announced it will report second quarter 2025 financial results on August 7, 2025, with a conference call and live webcast at 4:30 p.m. ET. Participants can join by dialing (800) 715-9871 or (646) 307-1963 with conference ID 5899895 or via webcast. Investors can submit questions via email to investorrelations@etonpharma.com. The webcast will be available on Eton’s website, with an archived version posted two hours post-e...
07-28 11:00
Eton gains as hormonal disorder therapy undergoes FDA review
Shares of Eton Pharmaceuticals (NASDAQ:ETON) added ~8% in the premarket on Tuesday after the FDA agreed to review its marketing application for ET-600, a potential treatment for a rare hormonal disord...
07-08 19:33
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
PRINCETON, N.J., July 8, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing prod...
07-08 19:30
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
Eton Pharmaceuticals announced the FDA acceptance of its New Drug Application (NDA) for ET-600, a proprietary desmopressin oral solution for treating central diabetes insipidus (AVP-D). The FDA has set a target action date of February 25, 2026, and the product is patented through 2044. ET-600 addresses a significant unmet need by offering an accurate, titratable liquid solution for pediatric patients. Eton has initiated commercial preparations fo...
07-08 10:50
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR
PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and...
07-02 19:00
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
Active Ingredient Manufacturing Transfer to the U.S. Complete PRINCETON, N.J., July 1, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharma...
07-01 19:30
Eton Pharmaceuticals to join Russell indexes
Eton Pharmaceuticals (NASDAQ:ETON) will be added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes, as part of the 2025 Russell Indexes reconstitution. The addition is effective afte...
06-27 19:12
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
Eton Pharmaceuticals, Inc., a biopharmaceutical company focused on developing treatments for rare diseases, has been added to the Russell 3000 and Russell 2000 Indexes. Effective June 27, 2025, this inclusion reflects Eton's strong performance and shareholder value generation over the past year. CEO Sean Brynjelsen highlighted the milestone as recognition of Eton's achievements and a step toward greater investor visibility. Eton currently has eig...
06-27 10:50
Grace Therapeutics Submits NDA To FDA For GTx-104; Submission Seeks Approval Of GTx-104 In Treatment Of Patients With Aneurysmal Subarachnoid Hemorrhage
Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of
06-25 20:02
